FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119464593> ?p ?o ?g. }

• W2119464593 endingPage "1168" @default.
• W2119464593 startingPage "1163" @default.
• W2119464593 abstract "OBJECTIVE To examine the safety and efficacy of switching from simvastatin to atorvastatin in patients who had either an inadequate lipid-lowering response with, or an adverse reaction to, simvastatin. PATIENTS AND METHODS The Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy (CAPISH) study was designed in 2 parts: a retrospective cohort study of patients (group A), identified from a large pharmacy database, who converted from simvastatin to atorvastatin at a single academic military medical center (between April 1998 and March 2002) and a prospective cohort study of patients (group B) monitored in a lipid clinic at the same institution (between April 2002 and March 2003). Group A was identified by 2 or more simvastatin prescription fills and at least 1 atorvastatin prescription fill. Group B was identified by a physician-perceived need to switch from simvastatin to atorvastatin. Clinical, pharmaceutical, and laboratory records of both cohorts were reviewed. RESULTS Approximately 1 in 4 simvastatin-treated patients discontinued therapy during a 4-year period. The most common reason for switching to atorvastatin was inadequate low-density lipoprotein (LDL) cholesterol control, although asymptomatic creatine kinase (CK) elevation and myalgias were also common. In most cases of myositis and in nearly all cases of rhabdomyolysis, patients were taking 80 mg of simvastatin. Achievement of National Cholesterol Education Program LDL cholesterol goals increased from 25% to 63% in group A and from 13% to 78% in group B, both P<.001. Significant reductions in CK also were seen in both groups. Adherence to atorvastatin was greater than 80% in both groups after 28.1±13.2 months (group A, 841 patients) and 8.1±3.8 months (group B, 104 patients). Among patients not taking atorvastatin at follow-up, 58% were no longer taking statins. CONCLUSION Atorvastatin was well tolerated in patients who previously were taking simvastatin. Serum lipid panels were improved substantially and CK levels were decreased without compromise to patient safety. To examine the safety and efficacy of switching from simvastatin to atorvastatin in patients who had either an inadequate lipid-lowering response with, or an adverse reaction to, simvastatin. The Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy (CAPISH) study was designed in 2 parts: a retrospective cohort study of patients (group A), identified from a large pharmacy database, who converted from simvastatin to atorvastatin at a single academic military medical center (between April 1998 and March 2002) and a prospective cohort study of patients (group B) monitored in a lipid clinic at the same institution (between April 2002 and March 2003). Group A was identified by 2 or more simvastatin prescription fills and at least 1 atorvastatin prescription fill. Group B was identified by a physician-perceived need to switch from simvastatin to atorvastatin. Clinical, pharmaceutical, and laboratory records of both cohorts were reviewed. Approximately 1 in 4 simvastatin-treated patients discontinued therapy during a 4-year period. The most common reason for switching to atorvastatin was inadequate low-density lipoprotein (LDL) cholesterol control, although asymptomatic creatine kinase (CK) elevation and myalgias were also common. In most cases of myositis and in nearly all cases of rhabdomyolysis, patients were taking 80 mg of simvastatin. Achievement of National Cholesterol Education Program LDL cholesterol goals increased from 25% to 63% in group A and from 13% to 78% in group B, both P<.001. Significant reductions in CK also were seen in both groups. Adherence to atorvastatin was greater than 80% in both groups after 28.1±13.2 months (group A, 841 patients) and 8.1±3.8 months (group B, 104 patients). Among patients not taking atorvastatin at follow-up, 58% were no longer taking statins. Atorvastatin was well tolerated in patients who previously were taking simvastatin. Serum lipid panels were improved substantially and CK levels were decreased without compromise to patient safety." @default.
• W2119464593 created "2016-06-24" @default.
• W2119464593 creator A5004678451 @default.
• W2119464593 creator A5005328949 @default.
• W2119464593 creator A5038939838 @default.
• W2119464593 creator A5044415837 @default.
• W2119464593 creator A5061138002 @default.
• W2119464593 creator A5061818791 @default.
• W2119464593 creator A5072012646 @default.
• W2119464593 date "2005-09-01" @default.
• W2119464593 modified "2023-10-12" @default.
• W2119464593 title "Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study" @default.
• W2119464593 cites W1825742435 @default.
• W2119464593 cites W1847859467 @default.
• W2119464593 cites W1967648308 @default.
• W2119464593 cites W1973459074 @default.
• W2119464593 cites W1982412102 @default.
• W2119464593 cites W1999226510 @default.
• W2119464593 cites W2006312678 @default.
• W2119464593 cites W2018711158 @default.
• W2119464593 cites W2019519444 @default.
• W2119464593 cites W2021042232 @default.
• W2119464593 cites W2031185570 @default.
• W2119464593 cites W2031825031 @default.
• W2119464593 cites W2032568924 @default.
• W2119464593 cites W2043361009 @default.
• W2119464593 cites W2046566499 @default.
• W2119464593 cites W2047026089 @default.
• W2119464593 cites W2050701294 @default.
• W2119464593 cites W2057674977 @default.
• W2119464593 cites W2059078444 @default.
• W2119464593 cites W2065618165 @default.
• W2119464593 cites W2081180316 @default.
• W2119464593 cites W2087666829 @default.
• W2119464593 cites W2089518306 @default.
• W2119464593 cites W2092100196 @default.
• W2119464593 cites W2094077837 @default.
• W2119464593 cites W2099355565 @default.
• W2119464593 cites W2103851590 @default.
• W2119464593 cites W2106343349 @default.
• W2119464593 cites W2129750583 @default.
• W2119464593 cites W2130873593 @default.
• W2119464593 cites W2134854746 @default.
• W2119464593 cites W2143833093 @default.
• W2119464593 cites W2154704322 @default.
• W2119464593 cites W2154817747 @default.
• W2119464593 cites W2155481867 @default.
• W2119464593 cites W2155598961 @default.
• W2119464593 cites W2159449551 @default.
• W2119464593 cites W2165924268 @default.
• W2119464593 cites W2321631825 @default.
• W2119464593 cites W2322095705 @default.
• W2119464593 cites W2397127108 @default.
• W2119464593 cites W2406971751 @default.
• W2119464593 cites W38523360 @default.
• W2119464593 cites W424467158 @default.
• W2119464593 doi "https://doi.org/10.4065/80.9.1163" @default.
• W2119464593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16178496" @default.
• W2119464593 hasPublicationYear "2005" @default.
• W2119464593 type Work @default.
• W2119464593 sameAs 2119464593 @default.
• W2119464593 citedByCount "23" @default.
• W2119464593 countsByYear W21194645932012 @default.
• W2119464593 countsByYear W21194645932014 @default.
• W2119464593 countsByYear W21194645932015 @default.
• W2119464593 crossrefType "journal-article" @default.
• W2119464593 hasAuthorship W2119464593A5004678451 @default.
• W2119464593 hasAuthorship W2119464593A5005328949 @default.
• W2119464593 hasAuthorship W2119464593A5038939838 @default.
• W2119464593 hasAuthorship W2119464593A5044415837 @default.
• W2119464593 hasAuthorship W2119464593A5061138002 @default.
• W2119464593 hasAuthorship W2119464593A5061818791 @default.
• W2119464593 hasAuthorship W2119464593A5072012646 @default.
• W2119464593 hasConcept C126322002 @default.
• W2119464593 hasConcept C167135981 @default.
• W2119464593 hasConcept C188816634 @default.
• W2119464593 hasConcept C197934379 @default.
• W2119464593 hasConcept C2776329913 @default.
• W2119464593 hasConcept C2776839432 @default.
• W2119464593 hasConcept C2777482532 @default.
• W2119464593 hasConcept C2778715236 @default.
• W2119464593 hasConcept C71924100 @default.
• W2119464593 hasConcept C72563966 @default.
• W2119464593 hasConcept C90924648 @default.
• W2119464593 hasConceptScore W2119464593C126322002 @default.
• W2119464593 hasConceptScore W2119464593C167135981 @default.
• W2119464593 hasConceptScore W2119464593C188816634 @default.
• W2119464593 hasConceptScore W2119464593C197934379 @default.
• W2119464593 hasConceptScore W2119464593C2776329913 @default.
• W2119464593 hasConceptScore W2119464593C2776839432 @default.
• W2119464593 hasConceptScore W2119464593C2777482532 @default.
• W2119464593 hasConceptScore W2119464593C2778715236 @default.
• W2119464593 hasConceptScore W2119464593C71924100 @default.
• W2119464593 hasConceptScore W2119464593C72563966 @default.
• W2119464593 hasConceptScore W2119464593C90924648 @default.
• W2119464593 hasIssue "9" @default.
• W2119464593 hasLocation W21194645931 @default.
• W2119464593 hasLocation W21194645932 @default.

• next